Partner David Rosen was featured in a Clinical Leader Q&A, “Clinical Trial Deaths — Will Clearer Informed Consent Documents Be Enough?” about issues related to clinical trial consent documents, particularly as they relate to the lawsuit filed against the FDA by the Center for Responsible Science, clinical trial participants and the father of a deceased trial participant.
Rosen answered questions about whether or not the lawsuit will be successful, whether or not the current death rate from clinical trial treatments is concerning and what steps clinical trial stakeholders need to take to improve the informed consent process and make trials safer for patients.
Rosen answered questions about whether or not the lawsuit will be successful, whether or not the current death rate from clinical trial treatments is concerning and what steps clinical trial stakeholders need to take to improve the informed consent process and make trials safer for patients.
People
Related News
March 12, 2026
In the News
Louis Lehot Explores M&A's Growing Blitzhire Phenomenon
Foley & Lardner LLP partner Louis Lehot authors article on the emergence of blitzhires in the Mergers & Acquisitions article, “Blitzhires: The New Fast-Moving M&A Deal.”
March 4, 2026
In the News
Christopher Ward Analyzes Uncertain Future of State Captive‑Audience Laws
Foley & Lardner LLP partner Christopher Ward was quoted in the Law360 article, “State Captive Audience Bans Live On Despite Uncertainty,” analyzing the legal status and future prospects for state laws restricting captive audience meetings.
March 3, 2026
In the News
Patrick Daugherty Assesses Growing Popularity of Crypto ATMs
Foley & Lardner LLP partner Patrick Daugherty assessed the growing popularity of crypto ATMs in the C-Store Dive article, “Navigating the pros and cons of crypto ATMs for convenience retailers.”